Jens U Marquardt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6374141/publications.pdf

Version: 2024-02-01

100 papers	4,344 citations	101384 36 h-index	118652 62 g-index
103 all docs	103 docs citations	103 times ranked	7713 citing authors

#	Article	IF	Citations
1	Genetic variation inTERTmodifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. Gut, 2023, 72, 381-391.	6.1	19
2	Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yesâ€Associated Protein 1 Activation and Transient Expansion of Stemâ€Like Cancer Cells. Hepatology Communications, 2022, 6, 1140-1156.	2.0	6
3	Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers. Cancers, 2022, 14, 1722.	1.7	26
4	The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. Hepatology Communications, 2022, 6, 1213-1226.	2.0	9
5	GDF11 restricts aberrant lipogenesis and changes in mitochondrial structure and function in human hepatocellular carcinoma cells. Journal of Cellular Physiology, 2021, 236, 4076-4090.	2.0	11
6	High pretreatment static and dynamic alphaâ€fetoprotein values predict reduced overall survival in hepatocellular carcinoma. United European Gastroenterology Journal, 2021, 9, 388-397.	1.6	4
7	Functional inhibition of Oct leads to HNF4Î± upregulation. Experimental and Therapeutic Medicine, 2021, 21, 349.	0.8	0
8	The Consumption of Cholesterol-Enriched Diets Conditions the Development of a Subtype of HCC with High Aggressiveness and Poor Prognosis. Cancers, 2021, 13, 1721.	1.7	13
9	Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma. Journal of Clinical Medicine, 2021, 10, 2803.	1.0	14
10	The Coâ€mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusionâ€Driven Cholangiocarcinoma. Hepatology, 2021, 74, 1357-1370.	3.6	13
11	Epigenetic modifications precede molecular alterations and drive human hepatocarcinogenesis. JCI Insight, 2021, 6, .	2.3	9
12	Tailored Systemic Therapy for Colorectal Cancer Liver Metastases. International Journal of Molecular Sciences, 2021, 22, 11780.	1.8	7
13	Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. Hepatology, 2020, 72, 88-102.	3.6	76
14	Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis. Cell Communication and Signaling, 2020, 18, 166.	2.7	21
15	Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. Cancers, 2020, 12, 2495.	1.7	12
16	Cluster of differentiation 44 promotes osteosarcoma progression in mice lacking the tumor suppressor Merlin. International Journal of Cancer, 2020, 147, 2564-2577.	2.3	3
17	BAX Redistribution Induces Apoptosis Resistance and Selective Stress Sensitivity in Human HCC. Cancers, 2020, 12, 1437.	1.7	11
18	Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies. Clinical and Translational Gastroenterology, 2020, 11, e00172.	1.3	21

#	Article	IF	Citations
19	NOTCH target gene HES5 mediates oncogenic and tumor suppressive functions in hepatocarcinogenesis. Oncogene, 2020, 39, 3128-3144.	2.6	28
20	Severe metabolic alterations in liver cancer lead to ERK pathway activation and drug resistance. EBioMedicine, 2020, 54, 102699.	2.7	36
21	Deletion of organic cation transporter Oct3 promotes hepatic fibrosis via upregulation of TGFÎ². American Journal of Physiology - Renal Physiology, 2019, 317, G195-G202.	1.6	11
22	Longâ€term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre. United European Gastroenterology Journal, 2019, 7, 838-849.	1.6	23
23	Context-Dependent Role of NF-ÎºB Signaling in Primary Liver Cancerâ€"from Tumor Development to Therapeutic Implications. Cancers, 2019, 11, 1053.	1.7	46
24	GDF11 exhibits tumor suppressive properties in hepatocellular carcinoma cells by restricting clonal expansion and invasion. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1540-1554.	1.8	22
25	Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. United European Gastroenterology Journal, 2019, 7, 529-537.	1.6	16
26	YAP-dependent induction of UHMK1 supports nuclear enrichment of the oncogene MYBL2 and proliferation in liver cancer cells. Oncogene, 2019, 38, 5541-5550.	2.6	45
27	Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma. Journal of Hepatology, 2019, 71, 323-332.	1.8	11
28	The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies. Targeted Oncology, 2019, 14, 115-123.	1.7	19
29	Murine Liver Organoids as a Genetically Flexible System to Study Liver Cancer In Vivo and In Vitro. Hepatology Communications, 2019, 3, 423-436.	2.0	25
30	Predisposition to Apoptosis in Hepatocellular Carcinoma: From Mechanistic Insights to Therapeutic Strategies. Frontiers in Oncology, 2019, 9, 1421.	1.3	29
31	Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy. European Journal of Internal Medicine, 2019, 60, 96-100.	1.0	24
32	Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 387-402.	4.2	18
33	Application of patientâ€derived liver cancer cells for phenotypic characterization and therapeutic target identification. International Journal of Cancer, 2019, 144, 2782-2794.	2.3	19
34	Cholesterol burden in the liver induces mitochondrial dynamic changes and resistance to apoptosis. Journal of Cellular Physiology, 2019, 234, 7213-7223.	2.0	67
35	Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease. United European Gastroenterology Journal, 2018, 6, 238-246.	1.6	17
36	The role of molecular enrichment on future therapies in hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 237-247.	1.8	95

#	Article	IF	Citations
37	Recombinant human hepatocyte growth factor provides protective effects in cerulein‚Äêinduced acute pancreatitis in mice. Journal of Cellular Physiology, 2018, 233, 9354-9364.	2.0	16
38	Immunotherapy of Hepatocellular Carcinoma. Oncology Research and Treatment, 2018, 41, 292-297.	0.8	27
39	The immune contexture of hepatocellular carcinoma predicts clinical outcome. Scientific Reports, 2018, 8, 5351.	1.6	93
40	Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Digestive Diseases, 2018, 36, 78-88.	0.8	7
41	The Role of Transforming Growth Factor-Î² in Human Hepatocarcinogenesis: Mechanistic and Therapeutic Implications From an Integrative Multiomics Approach. Gastroenterology, 2018, 154, 17-20.	0.6	11
42	Cytoplasmic localization of the cell polarity factor scribble supports liver tumor formation and tumor cell invasiveness. Hepatology, 2018, 67, 1842-1856.	3.6	48
43	Ginkgo biloba induces different gene expression signatures and oncogenic pathways in malignant and non-malignant cells of the liver. PLoS ONE, 2018, 13, e0209067.	1.1	13
44	Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC. European Journal of Internal Medicine, 2018, 55, 57-65.	1.0	6
45	Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer. Gastroenterology, 2017, 152, 2037-2051.e22.	0.6	118
46	Mitochondrial BAX Determines the Predisposition to Apoptosis in Human AML. Clinical Cancer Research, 2017, 23, 4805-4816.	3.2	26
47	Use of inhibitors of the renin‚Äêangiotensin system is associated with longer survival in patients with hepatocellular carcinoma. United European Gastroenterology Journal, 2017, 5, 987-996.	1.6	49
48	Cholesterol overload in the liver aggravates oxidative stress-mediated DNA damage and accelerates hepatocarcinogenesis. Oncotarget, 2017, 8, 104136-104148.	0.8	33
49	Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 65-91.	0.1	2
50	Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas. Oncotarget, 2017, 8, 48688-48700.	0.8	15
51	Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis. Oncotarget, 2017, 8, 115667-115680.	0.8	16
52	Loss of c-Met signaling sensitizes hepatocytes to lipotoxicity and induces cholestatic liver damage by aggravating oxidative stress. Toxicology, 2016, 361-362, 39-48.	2.0	19
53	DNMT1 is a required genomic regulator for murine liver histogenesis and regeneration. Hepatology, 2016, 64, 582-598.	3.6	45
54	Deconvolution of the cellular origin in hepatocellular carcinoma: Hepatocytes take the center stage. Hepatology, 2016, 64, 1020-1023.	3.6	9

#	Article	IF	Citations
55	Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype. Hepatology, 2016, 63, 1888-1899.	3.6	40
56	Surveillance of Hepatocellular Carcinoma and Diagnostic Algorithms in Patients with Liver Cirrhosis. Visceral Medicine, 2016, 32, 110-115.	0.5	9
57	The 9th Annual Conference of the International Liver Cancer Association (ILCA) 2015. Hepatic Oncology, 2016, 3, 9-12.	4.2	0
58	Increased liver carcinogenesis and enrichment of stem cell properties in livers of Dickkopf 2 (Dkk2) deleted mice. Oncotarget, 2016, 7, 28903-28913.	0.8	6
59	Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer, 2015, 15, 210.	1.1	87
60	Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!. Journal of Cancer Research and Clinical Oncology, 2015, 141, 515-522.	1.2	10
61	Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. Hepatic Oncology, 2015, 2, 79-93.	4.2	16
62	Curcumin effectively inhibits oncogenic NF-Î¹ºB signaling and restrains stemness features in liver cancer. Journal of Hepatology, 2015, 63, 661-669.	1.8	237
63	Functional and genetic deconstruction of the cellular origin in liver cancer. Nature Reviews Cancer, 2015, 15, 653-667.	12.8	249
64	Translating bioinformatics in oncology: guilt-by-profiling analysis and identification of KIF18B and CDCA3 as novel driver genes in carcinogenesis. Bioinformatics, 2015, 31, 216-224.	1.8	63
65	Next-Generation Genomic Profiling of Hepatocellular Adenomas: A New Era of Individualized Patient Care. Cancer Cell, 2014, 25, 409-411.	7.7	7
66	Regulation of microRNAs and their role in liver development, regeneration and disease. International Journal of Biochemistry and Cell Biology, 2014, 54, 288-303.	1.2	62
67	Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. Journal of Hepatology, 2014, 60, 346-353.	1.8	85
68	Epigenetic reprogramming modulates malignant properties of human liver cancer. Hepatology, 2014, 59, 2251-2262.	3.6	75
69	SnapShot: Hepatocellular Carcinoma. Cancer Cell, 2014, 25, 550-550.e1.	7.7	73
70	MYC Activates Stem-like Cell Potential in Hepatocarcinoma by a p53-Dependent Mechanism. Cancer Research, 2014, 74, 5903-5913.	0.4	71
71	Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2. Cancer Research, 2014, 74, 4752-4761.	0.4	74
72	Common variants in the HLA-DQ region confer susceptibility to idiopathic achalasia. Nature Genetics, 2014, 46, 901-904.	9.4	104

#	Article	IF	Citations
73	MicroRNAs as Novel Targets in Liver Cancer: Facing the Clinical Challenge. , 2014, , 157-174.		0
74	Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology, 2013, 58, 1054-1064.	3.6	138
75	Next generation sequencing of HCC from European and Asian HCC cohorts. Back to p53 and Wnt/Î²-catenin. Journal of Hepatology, 2013, 58, 622-624.	1.8	11
76	The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. Digestive and Liver Disease, 2013, 45, 408-413.	0.4	31
77	Modeling Pathogenesis of Primary Liver Cancer in Lineage-Specific Mouse Cell Types. Gastroenterology, 2013, 145, 221-231.	0.6	153
78	Sall4 in â€œStemnessâ€•Driven Hepatocarcinogenesis. New England Journal of Medicine, 2013, 368, 2316-2318.	13.9	13
79	Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling. Genes and Development, 2013, 27, 1706-1717.	2.7	90
80	Epigenetic regulation of methionine adenosyltransferase 1A: A role for MicroRNA-based treatment in liver cancer?. Hepatology, 2013, 57, 2081-2084.	3.6	7
81	Linking MLL and the HGF-MET signaling pathway in liver cancer. Journal of Clinical Investigation, 2013, 123, 2780-2783.	3.9	11
82	Next-Generation Sequencing: Application in Liver Cancerâ€”Past, Present and Future?. Biology, 2012, 1, 383-394.	1.3	16
83	Identification of RARRES1 as a core regulator in liver fibrosis. Journal of Molecular Medicine, 2012, 90, 1439-1447.	1.7	10
84	Novel insights in the genetics of HCC recurrence and advances in transcriptomic data integration. Journal of Hepatology, 2012, 56, 279-281.	1.8	19
85	Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): An emerging field for advanced technologies. Journal of Hepatology, 2012, 56, 267-275.	1.8	150
86	Snapshot liver transcriptome in hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 990-992.	1.8	11
87	Loss of c-Met accelerates development of liver fibrosis in response to CCl4 exposure through deregulation of multiple molecular pathways. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 942-951.	1.8	62
88	RNA-Seq Atlasâ€”a reference database for gene expression profiling in normal tissue by next-generation sequencing. Bioinformatics, 2012, 28, 1184-1185.	1.8	178
89	Contribution of Hepatic Lineage Stageâ€Specific Donor Memory to the Differential Potential of Induced Mouse Pluripotent Stem Cells. Stem Cells, 2012, 30, 997-1007.	1.4	47
90	Hepatocyte growth factor/c-metsignaling is required for stem-cell-mediated liver regeneration in mice. Hepatology, 2012, 55, 1215-1226.	3.6	159

#	Article	IF	Citations
91	The functional cancer map: A systems-level synopsis of genetic deregulation in cancer. BMC Medical Genomics, 2011, 4, 53.	0.7	36
92	Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology, 2011, 54, 1031-1042.	3.6	72
93	Neighbor of punc E11, a novel oncofetal marker for hepatocellular carcinoma. International Journal of Cancer, 2011, 128, 2353-2363.	2.3	15
94	Pulmonary Resection for Metastatic Gastric Cancer. Journal of Thoracic Oncology, 2010, 5, 1796-1805.	0.5	33
95	An Integrated Genomic and Epigenomic Approach Predicts Therapeutic Response to Zebularine in Human Liver Cancer. Science Translational Medicine, 2010, 2, 54ra77.	5.8	92
96	Definition of Ubiquitination Modulator COP1 as a Novel Therapeutic Target in Human Hepatocellular Carcinoma. Cancer Research, 2010, 70, 8264-8269.	0.4	65
97	Stem Cells in Hepatocarcinogenesis: Evidence from Genomic Data. Seminars in Liver Disease, 2010, 30, 026-034.	1.8	50
98	Platelets in Regeneration. Seminars in Thrombosis and Hemostasis, 2010, 36, 175-184.	1.5	68
99	Loss of c-Met Disrupts Gene Expression Program Required for G2/M Progression during Liver Regeneration in Mice. PLoS ONE, 2010, 5, e12739.	1.1	66
100	Genetic variation in normal tissue toxicity induced by ionizing radiation. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 667, 58-69.	0.4	86